Microbicides for multidrug-resistant and multitropic HIV-1

Current Opinion in Investigational Drugs

Volumn 9, Issue 2, 2008, Pages 152-169

  D'Cruz, O J ^a   Uckun, F M ^a  

^a Paradigm Pharmaceuticals   (United States)

Author keywords

HIV AIDS; Microbicide; Multidrug resistant HIV 1; Prodrug; Rational drug design; Sexual transmission; Thiourea NNRTI

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DAPIVIRINE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; HI 443; LAMIVUDINE; MICROBICIDE; NELFINAVIR; NEVIRAPINE; STAMPIDINE; STAVUDINE; TENOFOVIR; THIOUREA; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; PREVENTION AND CONTROL; REVIEW; SEXUAL TRANSMISSION; VIRUS TRANSMISSION;

ANIMALS; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; DIDEOXYNUCLEOTIDES; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; PYRIDINES; STAVUDINE; THIOUREA; THYMIDINE MONOPHOSPHATE;

EID: 38849166732     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (196)

1. D'Cruz OJ, Uckun FM: Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des (2004) 10(3):315-336. •• An in-depth analysis of the strengths and weaknesses of a number of topical strategies for HIV-1 prevention.
2. UNAIDS AIDS epidemic update: December 2007. UNAIDS, Geneva, Switzerland (2007). http://data.unaids.org/pub/EPISlides/2007/ 2007_epiupdate_en.pdf.
3. National Institute of Allergy and Infectious Diseases Fact Sheet: HIV infection and AIDS: An overview. National Institutes of Health, Bethesda, MD, USA (2005). http://www.niaid.nih.gov/factsheets/hivinf.htm.
4. Comparison of female-to-male and male-to-female transmission of HIV in 563 stable couples. Br Med J (1992) 304(6830):809-813.
5. D'Cruz OJ, Uckun FM: Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J Antimicrob Chemother (2006) 57(3):411-423. •• This paper and reference [6••] describe the unique features of rationally designed-tight binding NNRTIs as a new group of anti-HIV-1 microbicides.
6. D'Cruz OJ, Uckun FM: Novel broad-spectrum thiourea nonnucleoside inhibitors for the prevention of mucosal HIV transmission. Curr HIV Res (2006) 4(3):329-345. •• This paper and reference [5••] describe the unique features of rationally designed tight-binding thiourea NNRTIs as a new class of anti-HIV-1 microbicides.
7. D'Cruz OJ, Waurzyniak B, Uckun FM: Antiretroviral spermicide WHI-07 prevents vaginal and rectal transmission of feline immunodeficiency virus in domestic cats. Antimicrob Agents Chemother (2004) 48(4):1082-1088. •• This paper discusses the utility of nucleoside prodrugs as topical antiretroviral agents.
8. Uckun FM, D'Cruz OJ: Prophylactic contraceptives for HIV/AIDS. Human Reprod Update (1999) 5(5):506-514.
9. Kozal MJ, Amico KR, Chiarella J, Schreibman T, Cornman D, Fisher W, Fisher J, Friedland G: Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care. AIDS (2004) 18(16):2185-2189.
10. Madan RP, Keller MJ, Herold BC: Prioritizing prevention of HIV and sexually transmitted infections: First-generation vaginal microbicides. Curr Opin Infect Dis (2006) 19(1):49-54.
11. Cone RA, Hoen T, Wong X, Abusuwwa R, Anderson DJ, Moench TR: Vaginal microbicides: Detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis (2006) 6:90.
12. Berlier W, Bourlet T, Lawrence P, Hamzeh H, Lambert C, Genin C, Verrier B, Dieu-Nosjean MC, Pozzetto B, Delézay O: Selective sequestration of X4 isolates by human genital epithelial cells: Implication for virus tropism selection process during sexual transmission of HIV. J Med Virol (2005) 77(4):465-474.
13. Benki S, Mostad SB, Richardson BA, Mandaliya K, Kreiss JK, Overbaugh J: Cyclic shedding of HIV-1 RNA in cervical secretions during the menstrual cycle. J Infect Dis (2004) 189(12):2192-2201.
14. Quayle AJ, Xu C, Mayer KH, Anderson DJ: T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen. J Infect Dis (1997) 176(4):960-968. • This study provides evidence that seminal leukocytes are the major source of HIV-1 infected cells in semen.
15. Bagasra O, Farzadegan H, Seshamma T, Oakes JW, Saah A, Pomerantz RJ: Detection of HIV-1 proviral DNA in sperm from HIV-1-infected men. AIDS (1994) 8(12):1669-1674.
16. Kawamura T, Gulden FO, Sugaya M, McNamara DT, Borris DL, Lederman MM, Orenstein JM, Zimmerman PA, Blauvelt A: R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci USA (2003) 100(14):8401- 8406.
17. Mayer KH, Anderson DJ: Heterosexual HIV transmission. Infect Agents Dis (1995) 4(4):273-284.
18. Wright TC, Subbarao S, Ellerbrock TV, Lennox JL, Evans-Strickfaden T, Smith DG, Hart CE: Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. Am J Obstet Gynecol (2001) 184(3):279-285.
19. Prakash M, Patterson S, Kapembwa MS: Hormonal upregulation of CCR5 expression on T lymphocytes as a possible mechanism for increased HIV-1 risk. J Acquir Immune Defic Syndr (2005) 38(Suppl 1):S14-S16.
20. Phillips DM, Sudol KM, Taylor CL, Guichard L, Elsen R, Maguire RA: Lubricants containing N-9 may enhance rectal transmission of HIV and other STIs. Contraception (2004) 70(2):107-110.
21. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiègne-Traoré V, Uaheowitchai C, Karim SS et al: Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial. Lancet (2002) 360(9338):971-977.
22. Chakraborty H, Sen PK, Helms RW, Vernazza PL, Fiscus SA, Eron JJ, Patterson BK, Coombs RW, Krieger JN, Cohen MS: Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: A probabilistic empiric model. AIDS (2001) 15(5):621-627.
23. Pilcher CD, Tien HC, Eron JJ, Vernazza PL, Leu SY, Stewart PW, Goh LE, Cohen MS: Brief but efficient: Acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 189(10):1785-1792.
24. Sternberg SS (Ed): Histology for Pathologists. Raven Press, New York, NY, USA (1992).
25. Di Stefano M, Favia A, Monno L, Lopalco P, Caputi O, Scardigno AC, Pastore G, Fiore JR, Angarano G: Intracellular and cellfree (infectious) HIV-1 in rectal mucosa. J Med Virol (2001) 65(4):637-643.
26. Gurney KB, Elliott J, Nassanian H, Song C, Soilleux E, McGowan I, Anton PA, Lee B: Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa. J Virol (2005) 79(9):5762-5773.
27. Lore K, Larsson M: The role of dendritic cells in the pathogenesis of HIV-1 infection. APMIS (2003) 111(7-8):776-788. • This paper reviews two routes for the transepithelial migration of HIV-1-infected cells.
28. Cohn MA, Frankel SS, Rugpao S, Young MA, Willett G, Tovanabutra S, Khamboonruang C, VanCott T, Bhoopat L, Barrick S, Fox C et al: Chronic inflammation with increased human immunodeficiency virus (HIV) RNA expression in the vaginal epithelium of HIV-infected Thai women. J Infect Dis (2001) 184(4):410-417.
29. Tchou I, Misery L, Sabido O, Dezutter-Dambuyant C, Bourlet T, Moja P, Hamzeh H, Peguet-Navarro J, Schmitt D, Genin C: Functional HIV CXCR4 coreceptor on human epithelial Langerhans cells and infection by HIV strain X4. J Leukoc Biol (2001) 70(2):313-321.
30. Starr-Spires LD, Collman RG: HIV-1 entry and entry inhibitors as therapeutic agents. Clin Lab Med (2002) 22(3):681-701.
31. O'Hara BM, Olson WC: HIV entry inhibitors in clinical development. Curr Opin Pharmacol (2002) 2(5):523-528.
32. Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, Sodroski J, Zhao L, Olson W, Kwong PD, Sattentau QJ: Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol (2000) 74(4):1948-1960.
33. Meng G, Wei X, Wu X, Sellers MT, Decker JM, Moldoveanu Z, Orenstein JM, Graham MF, Kappes JC, Mestecky J, Shaw GM et al: Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells. Nat Med (2002) 8(2):150-156.
34. Kwa D, Vingerhoed J, Boeser B, Schuitemaker H: Increased in vitro cytopathicity of CC chemokine receptor 5-restricted human immunodeficiency virus type 1 primary isolates correlates with a progressive clinical course of infection. J Infect Dis (2003) 187(9):1397-1403.
35. Mosier DE: Virus and target cell evolution in human immunodeficiency virus type 1 infection. Immunol Res (2000) 21(2-3):253-258.
36. Howell AL, Asin SN, Yeaman GR, Wira CR: HIV-1 infection of the female reproductive tract. Curr HIV/AIDS Rep (2005) 2(1):35-38.
37. McClure CP, Tighe PJ, Robins RA, Bansal D, Bowman CA, Kingston M, Ball JK: HIV coreceptor and chemokine ligand gene expression in the male urethra and female cervix. AIDS (2005) 19(12):1257-1265.
38. Moore JP, Kitchen SG, Pugach P, Zack JA: The CCR5 and CXCR4 coreceptors - central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses (2004) 20(1):111-126.
39. Polzer S, Dittmar MT, Schmitz H, Schreiber M: The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization. Virology (2002) 304(1):70-80.
40. Clevestig P, Pramanik L, Leitner T, Ehrnst A: CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site. J Gen Virol (2006) 87(3):607-612.
41. Rosen O, Sharon M, Quadt-Akabayov SR, Anglister J: Molecular switch for alternative conformations of the HIV-1 V3 region: Implications for phenotype conversion. Proc Natl Acad Sci USA (2006) 103(38):13950- 13955.
42. Galvani AP, Novembre J: The evolutionary history of the CCR5-?32 HIV-resistance mutation. Microbes Infect (2005) 7(2):302-309.
43. Zhang H, Orti G, Du Q, He J, Kankasa C, Bhat G Wood C: Phylogenetic and phenotypic analysis of HIV type 1 env gp120 in cases of subtype C mother-to-child transmission. AIDS Res Hum Retroviruses (2002) 18(18):1415-1423.
44. Papathanasopoulos MA, Hunt GM, Tiemessen CT: Evolution and diversity of HIV-1 in Africa - a review. Virus Genes (2003) 26(2):151-163.
45. Janini LM, Tanuri A, Schechter M, Peralta JM, Vicente AC, Dela Torre N, Pieniazek NJ, Luo CC, Ramos A, Soriano V, Schochetman G et al: Horizontal and vertical transmission of human immunodeficiency virus type 1 dual infections caused by viruses of subtypes B and C. J Infect Dis (1998) 177(1):227-231.
46. Quinn TC: Molecular variants of HIV-1 and their impact on vaccine development. Int J STD AIDS (1998) 9(Suppl 1):2.
47. Soares EA, Martínez AM, Souza TM, Santos AF, Da Hora V, Silveira J, Bastos FI, Tanuri A, Soares MA: HIV-1 subtype C dissemination in southern Brazil. AIDS (2005) 19(Suppl 4):S81-S86.
48. Hu DJ, Vanichseni S, Mastro TD, Raktham S, Young NL, Mock PA, Subbarao S, Parekh BS, Srisuwanvilai L, Sutthent R, Wasi C et al: Viral load differences in early infection with two HIV-1 subtypes. AIDS (2001) 15(6):683-691.
49. John-Stewart GC, Nduati RW, Rousseau CM, Mbori-Ngacha DA, Richardson BA, Rainwater S, Panteleeff DD, Overbaugh J: Subtype C is associated with increased vaginal shedding of HIV-1. J Infect Dis (2005) 192(3):492-496.
50. Atlas A, Thanh Ha TT, Lindström A, Nilsson A, Alaeus A, Chiodi F, De Milito A: Effects of potent antiretroviral therapy on the immune activation marker soluble CD27 in patients infected with HIV-1 subtypes A-D. J Med Virol (2004) 72(3):345-351.
51. Flys TS, Chen S, Jones DC, Hoover DR, Church JD, Fiscus SA, Mwatha A, Guay LA, Mmiro F, Musoke P, Kumwenda N et al: Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr (2006) 42(5):610-613.
52. Zhang L, He T, Huang Y, Chen Z, Guo Y, Wu S, Kunstman KJ, Brown RC, Phair JP, Neumann AU, Ho DD et al: Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1. J Virol (1998) 72(11):9307-9312.
53. Tscherning C, Alaeus A, Fredriksson R, Björndal A, Deng H, Littman DR, Fenyö EM, Albert J: Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology (1998) 241(2):181-188.
54. Renjifo B, Gilbert P, Chaplin B, Msamanga G, Mwakagile D, Fawzi W, Essex M: Preferential in-utero transmission of HIV-1 subtype C as compared to HIV-1 subtype A or D. AIDS (2004) 18(12):1629- 1636.
55. Desfosses Y, Solis M, Sun Q, Grandvaux N, Van Lint C, Burny A, Gatignol A, Wainberg MA, Lin R, Hiscott J: Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins. J Virol (2005) 79(14):9180-9191.
56. Ramos A, Tanuri A, Schechter M, Rayfield MA, Hu DJ, Cabral MC, Bandea CI, Baggs J, Pieniazek D: Dual and recombinant infections: An integral part of the HIV-1 epidemic in Brazil. Emerg Infect Dis (1999) 5(1):65-74.
57. Flores I, Pieniazek D, Morán N, Soler A, Rodríguez N, Alegría M, Vera M, Janini LM, Bandea CI, Ramos A, Rayfield M et al: HIV-1 subtype F in single and dual infections in Puerto Rico: A potential sentinel site for monitoring novel genetic HIV variants in North America. Emerg Infect Dis (1999) 5(3):481-483.
58. HIV databases. Los Alamos National Security LLC, Los Alamos, NM, USA (2006). http://hiv-web.lanl.gov/content.
59. Morison L, Buvé A, Zekeng L, Heyndrickx L, Anagonou S, Musonda R, Kahindo M, Weiss HA, Hayes RJ, Laga M, Janssens W et al: HIV-1 subtypes and the HIV epidemics in four cities in sub-Saharan Africa. AIDS (2001) 15(Suppl 4):S109-S116.
60. De Clercq E: Antiviral drugs in current clinical use. J Clin Virol (2004) 30(2):115-133.
61. Gulick RM: New antiretroviral drugs. Clin Microbiol Infect (2003) 9(3):186-193.
62. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD et al: Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel. J Am Med Assoc (2000) 283(3):381-390.
63. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 338(13):853-860.
64. Smit C, Geskus R, Uitenbroek D, Mulder D, Van Den Hoek A, Coutinho RA, Prins M: Declining AIDS mortality in Amsterdam: Contributions of declining HIV incidence and effective therapy. Epidemiology (2004) 15(5):536-542.
65. Craigo JK, Patterson BK, Paranjpe S, Kulka K, Ding M, Mellors J, Montelaro RC, Gupta P: Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy. AIDS Res Hum Retroviruses (2004) 20(11):1196-1209.
66. Moyle GJ: Current knowledge of HIV-1 reverse transcriptase mutations selected during nucleoside analogue therapy: The potential to use resistance data to guide clinical decisions. J Antimicrob Chemother (1997) 40(6):765-777.
67. Drosopoulos WC, Rezende LF, Wainberg MA, Prasad VR: Virtues of being faithful: Can we limit the genetic variation in human immunodeficiency virus? J Mol Med (1998) 76(9):604-612.
68. Aguiar RS, Pereira HS, Costa LJ, Brindeiro RM, Tanuri A: Gag-Pol bearing a reverse transcriptase drug-resistant mutation influences viral genomic RNA incorporation into human immunodeficiency virus type 1 particles. J Gen Virol (2006) 87(9):2669-2677.
69. Wlodawer A: Structure-based design of AIDS drugs and the development of resistance. Vox Sang (2002) 83(Suppl 1):23-26.
70. Yin PD, Das D Mitsuya H: Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance. Cell Mol Life Sci (2006) 63(15):1706-1724.
71. Levin J: Transmission of drug resistance in newly infected. International HIV Drug Resistance Workshop (2003) 12: Conference Report. http://www.natap.org/2003/resistance/day6.htm.
72. Uckun FM, D'Cruz OJ: Therapeutic innovations against HIV. Exp Opin Ther Patents (2006) 16(3):265-293. •• An in-depth review of the anti-HIV agents currently in clinical use and new agents under development.
73. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA: Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science (1992) 256(5065):1783-1790. •• This paper reports the crystal structure of the NNRTI/HIV-1 RT complex.
74. Stammers DK, Somers DO, Ross CK, Kirby I, Ray PH, Wilson JE, Norman M, Ren JS, Esnouf RM, Garman EF, Jones EY et al: Crystals of HIV-1 reverse transcriptase diffracting to 2.2 Å resolution. J Mol Biol (1994) 242(4):586-588.
75. Tarrago-Litvak L, Andréola ML, Nevinsky GA, Sarih-Cottin L, Litvak S: The reverse transcriptase of HIV-1: From enzymology to therapeutic intervention. FASEB J (1994) 8(8):497-503.
76. Smerdon SJ, Jäger J, Wang J, Kohlstaedt LA, Chirino AJ, Friedman JM, Rice PA, Steitz TA: Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Natl Acad Sci USA (1994) 91(9):3911-3915.
77. 181Cys HIV-1 RT drug-resistant mutant. J Mol Biol (1996) 264(5):1085-1100.
78. Hsiou Y, Ding J, Das K, Clark AD, Hughes SH, Arnold E: Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: Implications of conformational changes for polymerization and inhibition mechanisms. Structure (1996) 4(7):853-860.
79. Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM: Structure-based drug design of non-nucleoside inhibitors for wildtype and drug-resistant HIV reverse transcriptase. Biochem Pharmacol (2000) 60(9):1251-1265.
80. Painter GR, Almond MR, Mao S, Liotta DC: Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase. Curr Top Med Chem (2004) 4(10):1035-1044.
81. Piliero PJ: Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr (2004) 37(Suppl 1):S2-S12.
82. Ray AS: Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase. AIDS Rev (2005) 7(2):113-125.
83. Peters S, Munoz M, Yerly S, Sanchez-Merino V, Lopez-Galindez C, Perrin L, Larder B, Cmarko D, Fakan S, Meylan P, Telenti A: Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein. J Virol (2001) 75(20):9644-9653.
84. Matsumi S, Kosalaraksa P, Tsang H, Kavlick MF, Harada S, Mitsuya H: Pathways for the emergence of multi-dideoxynucleoside-resistant HIV-1 variants. AIDS (2003) 17(8):1127-1137.
85. White KL, Chen JM, Margot NA, Wrin T, Petropoulos CJ, Naeger LK, Swaminathan S, Miller MD: Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations. Antimicrob Agents Chemother (2004) 48(3):992-1003.
86. Schafer R, Kantor R, Gonzales M: The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Rev (2000) 2:221-228.
87. Rhee SY, Fessel WJ, Zolopa AR, Hurley L, Liu T, Taylor J, Nguyen DP, Slome S, Klein D, Horberg M, Flamm J et al: HIV-1 Protease and reverse-transcriptase mutations: Correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis (2005) 192(3):456-465.
88. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, Clarke J, Sirivichayakul S, Soares MA, Snoeck J, Pillay C et al: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoS Med (2005) 2(4):e112.
89. Gonzales MJ, Wu TD, Taylor J, Belitskaya I, Kantor R, Israelski D, Chou S, Zolopa AR, Fessel WJ, Shafer RW: Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS (2003) 17(6):791-799.
90. Røge BT, Katzenstein TL, Obel N, Nielsen H, Kirk O, Pedersen C, Mathiesen L, Lundgren J, Gerstoft J: K65R with and without S68: A new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir Ther (2003) 8(2):173-182.
91. Gottlieb MS: AIDS - past and future. N Engl J Med (2001) 344(23):1788-1791.
92. Sepkowitz KA: AIDS - the first 20 years. N Engl J Med (2001) 344(23):1764-1772.
93. Richman DD: HIV chemotherapy. Nature (2001) 410(6831):995-1001.
94. Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, Manion D, Ruiz N, Gersten M, Becker M, McNamara J et al: Combination therapy with efavirenz, nelfinavir, and nucleoside reverse transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med (1999) 341(25):1874-1881.
95. Johnson VA: Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1. J Infect Dis (1995) 171(Suppl 2):S140-S149.
96. Lin PF, González CJ, Griffith B, Friedland G, Calvez V, Ferchal F, Schinazi RF, Shepp DH, Ashraf AB, Wainberg MA, Soriano V et al: Stavudine resistance: An update on susceptibility following prolonged therapy. Antivir Ther (1999) 4(1):21-28.
97. Coakley EP, Gillis JM, Hammer SM: Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS (2000) 14(2):F9-F15.
98. Ross L, Scarsella A, Raffanti S, Henry K, Becker S, Fisher R, Liao Q, Hirani A, Graham N, St Clair M, Hernandez J: Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens. AIDS Res Hum Retroviruses (2001) 17(12):1107-1115.
99. Suzuki K, Kaufmann GR, Mukaide M, Cunningham P, Harris C, Leas L, Kondo M, Imai M, Pett SL, Finlayson R, Zaunders J et al: Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine. AIDS Res Hum Retroviruses (2001) 17(13):1293-1296.
100. Picard V, Angelini E, Maillard A, Race E, Clavel F, Chêne G, Ferchal F, Molina JM: Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. J Infect Dis (2001) 184(6):781-784.
101. Tozzi V, Zaccarelli M, Bonfigli S, Lorenzini P, Liuzzi G, Trotta MP, Forbici F, Gori C, Bertoli A, Bellagamba R, Narciso P et al: Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: Prevalence, risk factors and virological outcome. Antivir Ther (2006) 11(5):553-560.
102. Izopet J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, Puel J, Massip P: Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine. J Med Virol (1999) 59(4):507-511.
103. O'Brien WA: Resistance against reverse transcriptase inhibitors. Clin Infect Dis (2000) 30(Suppl 2):S185-S192.
104. Pillay D, Taylor S, Richman DD: Incidence and impact of resistance against approved antiretroviral drugs. Rev Med Virol (2000) 10(4):231-253.
105. Rousseau MN, Vergne L, Montes B, Peeters M, Reynes J, Delaporte E, Segondy M: Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 26(1):36-43.
106. Gutiérrez F, Moltó J, Escolano C, Mora A, Pasquau F, Gregori J, Nogueira E: Genotypic resistance to antiretroviral drugs in patients with therapeutic failure to highly active antiretroviral therapy. Med Clin (Barc) (2000) 115(11):401-404.
107. Palmer S, Shafer RW, Merigan TC: Highly drug resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS (1999) 13(6):661-667.
108. Hu DJ, Dondero TJ, Rayfield MA, George JR, Schochetman G, Jaffe HW, Luo CC, Kalish ML, Weniger BG, Pau CP, Schable CA et al: The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention. J Am Med Assoc (1996) 275(3):210- 216.
109. Kuiken CL, Foley B, Hahn BH, Korber B, McCutchan F, Marx PA, Mellors JW, Mullins JI, Sodroski J, Wolinksy S: A compilation and analysis of nucleic acid and amino acid sequences. Human Retroviruses and AIDS, Los Alamos National Laboratory, Los Alamos, NM, USA (1999).
110. Palmer S, Alaeus A, Albert J, Cox S: Drug susceptibility of subtypes A, B, C, D, and E human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses (1998) 14(2):157-162
111. Shafer RW, Eisen JA, Merigan TC, Katzenstein DA: Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. J Virol (1997) 71(7):5441-5448.
112. Palmer S, Margot N, Gilbert H, Shaw N, Buckheit R, Miller M: Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance. AIDS Res Hum Retroviruses (2001) 17(12):1167-1173.
113. Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M, Katzenstein DA: Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med (2001) 345(6):398-407.
114. Briones C, Soriano V, González-Lahoz J: Prevalence of drug-resistant HIV-1 genotypes in heavily pre-treated patients on current virological failure. AIDS (2000) 14(11):1659-1660.
115. Sharma PL, Nurpeisov V, Hernandez-Santiago B, Beltran T, Schinazi RF: Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Cur Top Med Chem (2004) 4(9):895-919.
116. Fontaine E, Van Vaerenbergh K, Vandamme A-M, Schmit J-C: Multidrug resistant human immunodeficiency virus type 1. AIDS Rev (1999) 1:231-237.
117. Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, Harrigan R, Staszewski S, Katlama C, Pearce G, Tisdale M: HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS (2000) 14(2):163- 171.
118. Lanier ER, Givens N, Stone C, Griffin P, Gibb D, Walker S, Tisdale M, Irlbeck D, Underwood M, St Clair M, Ait-Khaled M: Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens. HIV Med (2004) 5(6):394-399.
119. Vig R, Venkatachalam TK, Uckun FM: D4T-5′-[p- bromophenyl methoxyalaninyl phosphate] as a potent and non-toxic antihuman immunodeficiency virus agent. Antivir Chem Chemother (1998) 9(5):445-448.
120. Venkatachalam TK, Tai HL, Vig R, Chen CL, Jan ST, Uckun FM: Enhancing effects of a mono-bromo substitution at the para position of the phenyl moiety on the metabolism and anti-HIV activity of d4T-phenyl methoxyalaninyl phosphate derivatives. Bioorg Med Chem Lett (1998) 8(22):3121-3126.
121. Uckun FM, Pendergrass S, Venkatachalam TK, Qazi S, Richman D: Stampidine is a potent inhibitor of zidovudine- and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations. Antimicrob Agents Chemother (2002) 46(11):3613-3616.
122. Uckun FM, Pendergrass S, Qazi S, Venkatachalam TK: In vitro activity of stampidine against primary clinical human immunodeficiency virus isolates. Arzneimittelforschung (2004) 54(1):69-77.
123. Uckun FM, Venkatachalam TK, Qazi S: Potency of stampidine against multi-nucleoside reverse transcriptase inhibitor resistant human immunodeficiency viruses. Arzneimittel Forschung (2006) 56(2a):193-203.
124. Uckun FM, Qazi S, Venkatachalam TK: In vitro anti-HIV potency of stampidine alone and in combination with standard anti-HIV drugs. Arzneimittelforschung (2005) 55(4):223-231.
125. Zhang H, Dornadula G, Beumont M, Livornese L, Van Uitert B, Henning K, Pomerantz RJ: Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med (1998) 339(25):1803-1809.
126. Uckun FM, DuMez D, Qazi S, Tibbles H, Venkatachalam TK: Antiretroviral activity of GMP-grade stampidine against geno typically and phenotypically nucleoside reverse transcriptase inhibitor resistant recombinant human immunodeficiency virus. An in vitro study. Arzneimittelforschung (2007) 57(2):112-121.
127. Peeters M, Esu-Williams E, Vergne L, Montavon C, Mulanga-Kabeya C, Harry T, Ibironke A, Lesage D, Patrel D, Delaporte E: Predominance of subtype A and G HIV type 1 in Nigeria, with geographical differences in their distribution. AIDS Res Hum Retroviruses (2000) 16(4):315-325.
128. Yirrell DL, Kaleebu P, Morgan D, Watera C, Magambo B, Lyagoba F, Whitworth J: Inter- and intra-genic intersubtype HIV-1 recombination in rural and semi-urban Uganda. AIDS (2002) 16(2):279-286.
129. Steain MC, Wang B, Dwyer DE, Saksena NK: HIV-1 co-infection, superinfection and recombination. Sex Health (2004) 1(4):239-250.
130. Brenner B, Routy JP, Quan Y, Moisi D, Oliveira M, Turner D, Wainberg MA: Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS (2004) 18(12):1653-1660.
131. Smith DM, Wong JK, Hightower GK, Ignacio CC, Koelsch KK, Petropoulos CJ, Richman DD, Little SJ: HIV drug resistance acquired through superinfection. AIDS (2005) 19(12):1251-1256.
132. Moyle GJ, Basar A, Gazzard BG: Frequency of multinucleoside analogue-resistant genotypes observed during antiretroviral therapy. AIDS (2000) 14(9):1292-1293.
133. Moyle GJ, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whitcomb J, Gazzard BG: Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis (2005) 191(6):866-872.
134. Blackard JT, Cohen DE, Mayer KH: Human immunodeficiency virus superinfection and recombination: Current state of knowledge and potential clinical consequences. Clin Infect Dis (2002) 34(8):1108-1114.
135. Uckun FM, Qazi S, Pendergrass S, Lisowski E, Waurzyniak B, Chen CL, Venkatachalam TK: In vivo toxicity, pharmacokinetics, and anti-human immunodeficiency virus activity of stavudine-5′-(p-bromo phenyl methoxyalaninyl phosphate) (stampidine) in mice. Antimicrob Agents Chemother (2002) 46(11):3428-3436.
136. Uckun FM, Chen CL, Samuel P, Pendergrass S, Venkatachalam TK, Waurzyniak B, Qazi S: In vivo antiretroviral activity of stampidine in chronically feline immunodeficiency virus-infected cats. Antimicrob Agents Chemother (2003) 47(4):1233-1240.
137. Uckun FM, Chen CL, Lisowski E, Mitcheltree GC, Venkatachalam TK, Erbeck D, Chen H, Waurzyniak B: Toxicity and pharmacokinetics of stampidine in mice and rats. Arzneimittelforschung (2003) 53(5):357-367.
138. Chen CL, Yu G, Venkatachalam TK, Uckun FM: Metabolism of stavudine-5′-[p-bromophenyl methoxyalaninyl phosphate], stampidine, in mice, dogs, and cats. Drug Metab Dispos (2002) 30(12):1523-1531.
139. Uckun FM, Waurzyniak B, Tibbles H, Venkatachalam TK, Erbeck D: In vivo pharmacokinetics and toxicity profile of the anti-HIV agent stampidine in dogs and feline immunodeficiency virus-infected cats. Arzneimittelforschung (2006) 56(2a):176-192.
140. Schäfer W, Friebe WG, Leinert H, Mertens A, Poll T, von der Saal W, Zilch H, Nuber B, Ziegler ML: Non-nucleoside inhibitors of HIV-1 reverse transcriptase: Molecular modeling and X-ray structure investigations. J Med Chem (1993) 36(6):726-732.
141. Ren J, Esnouf RM, Hopkins AL, Warren J, Balzarini J, Stuart DI, Stammers DK: Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. Biochemistry (1998) 37(41):14394- 14403.
142. Ding J, Das K, Tantillo C, Zhang W, Clark AD Jr, Jessen S, Lu X, Hsiou Y, Jacobo-Molina A Andries K, Pauwels R et al: Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 Å resolution. Structure (1995) 3(4):365-379.
143. 188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the nonnucleoside inhibitor HBY 097: Inhibitor flexibility is a useful design feature for reducing drug resistance. J Mol Biol (1998) 284(2):313-323.
144. Esnouf R, Ren J, Ross C, Jones Y, Stammers D, Stuart D: Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nature Struct Biol (1995) 2(4):303-308.
145. Gatanaga H, Hachiya A, Kimura S, Oka S: Mutations other than 103N in human immunodeficiency virus type 1 reverse transcriptase (RT) emerge from K103R polymorphism under non-nucleoside RT inhibitor pressure. Virology (2006) 344(2):354-362.
146. Casado JL, Hertogs K, Ruiz L, Dronda F, Van Cauwenberge A, Arnó A, Garcia-Arata I, Bloor S, Bonjoch A, Blazquez J, Clotet B et al: Nonnucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. AIDS (2000) 14(2):F1-F7.
147. Joly V, Descamps D, Peytavin G, Touati F, Mentre F, Duval X, Delarue S, Yeni P, Brun-Vezinet F: Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs. Antimicrob Agents Chemother (2004) 48(1):172-175.
148. Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, Marlink RG, Schapiro J, Roger M, Wainberg MA: A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS (2003) 17(1):F1-F5.
149. Tang JW, Pillay D. Transmission of HIV-1 drug resistance. J Clin Virol (2004) 30(1):1-10.
150. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO: Time trends in primary HIV-1 drug resistance among recently infected persons. J Am Med Assoc (2002) 288(2):181-188.
151. de Mendoza C, Rodriguez C, Colomina J, Tuset C, Garcia F, Eiros JM, Corral A, Leiva P, Aguero J, Torre-Cisneros J, Pedreira J et al: Resistance to non-nucleoside reverse transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin Infect Dis (2005) 41(9):1350-1354.
152. Ren J, Nichols C, Bird L, Chamberlain P, Weaver K, Short S, Stuart DI, Stammers DK: Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J Mol Biol (2001) 312(4):795-805.
153. Ren J, Nichols CE, Chamberlain PP, Weaver KL, Short SA, Stammers DK: Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors. J Mol Biol (2004) 336(3):569-578.
154. Ren J, Nichols CE, Stamp A, Chamberlain PP, Ferris R, Weaver KL, Short SA, Stammers DK: Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138. FEBS J (2006) 273(16):3850-3860.
155. Artico M: Non-nucleoside anti-HIV-1 reverse transcriptase inhibitors (NNRTIs): A chemical survey from lead compounds to selected drugs for clinical trials. Farmaco (1996) 51(5):305-331.
156. Miller V, de Béthune MP, Kober A, Stürmer M, Hertogs K, Pauwels R, Stoffels P, Staszewski S: Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrob Agents Chemother (1998) 42(12):3123-3129.
157. Bacheler LT, Anton ED, Kudish P, Baker D, Bunville J, Krakowski K, Bolling L, Aujay M, Wang XV, Ellis D, Becker MF et al: Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother (2000) 44(9):2475-2484.
158. Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M, Katzenstein DA: Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. New Engl J Med (2001) 345(6):398-407.
159. Delaugerre C, Rohban R, Simon A, Mouroux M, Tricot C, Agher R, Huraux JM, Katlama C, Calvez V: Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol (2001) 65(3):445-448.
160. Clevenbergh P, Cua E, Dam E, Durant J, Schmit JC, Boulme R, Cottalorda J, Beyou A, Schapiro JM, Clavel F, Dellamonica P: Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naive HIV-infected patients. HIV Clinical Trials (2002) 3(1):36-44.
161. Piketty C, Gérard L, Chazallon C, Calvez V, Clavel F, Taburet AM, Girard PM, Aboulker JP: Virological and immunological impact of nonnucleoside reverse transcriptase inhibitor withdrawal in HIV-infected patients with multiple treatment failures. AIDS (2004) 18(10):1469-1471.
162. Hachiya A, Gatanaga H, Kodama E, Ikeuchi M, Matsuoka M, Harada S, Mitsuya H, Kimura S, Oka S: Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naive patients. Virology (2004) 327(2):215-224.
163. Vig R, Mao C, Venkatachalam TK, Tuel-Ahlgren L, Sudbeck EA, Uckun FM: Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reserve transcriptase. Bioorg Med Chem Lett (1998) 6(10):1789-1797. •• This paper describes the use of a novel composite NNRTI binding pocket for the rational design of broad-spectrum thiourea-based anti-HIV-1 agents.
164. Vig R, Mao C, Venkatachalam TK, Tuel-Ahlgren L, Sudbeck EA, Uckun FM: 5-Alkyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-ones as potent non-nucleoside reverse transcriptase inhibitors of S-DABO series. Bioorg Med Chem Lett (1998) 8(12):1461-1466.
165. Sudbeck EA, Mao C, Vig R, Venkatachalam TK, Tuel-Ahlgren L, Uckun FM: Structure-based design of novel dihydroalkoxy benzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother (1998) 42(12):3225-3233.
166. Mao C, Vig R, Venkatachalam TK, Sudbeck EA, Uckun FM: Structure-based design of N-[2-(1-piperidinylethyl)]-N′- [2-(5-bromopyridyl)]-thiourea and N- [2-(1-piperazinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett (1998) 8(16):2213-2218.
167. Uckun FM, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, Mao C, Venkatachalam TK: N′-[2-(2-thiophene)ethyl]-N′-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1. Bioorg Med Chem Lett (1999) 9(24):3411-3416.
168. Uckun FM, Mao C, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, Venkatachalam TK: N-[2-(1-cyclohexenyl)ethyl]-N′-[2-(5-bromopyridyl)]-thiourea and N′-[2-(1- cyclohexenyl)ethyl]-N′-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1. Bioorg Med Chem Lett (1999) 9(18):2721-2726.
169. Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM: Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N′-[2-(5- bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drugresistant human immunodeficiency virus. Bioorg Med Chem Lett (1999) 9(11):1593-1598.
170. Venkatachalam TK, Sudbeck EA, Mao C, Uckun FM: Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett (2000) 10(18):2071-2074.
171. Uckun FM, Mao C, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, Venkatachalam TK: N-[2-(4-methylphenyl)ethyl]-N′-[2-(5-bromopyridyl)]-thiourea as a potent inhibitor of NNRTI-resistant and multidrug-resistant human immunodeficiency virus type 1. Antivir Chem Chemother (2000) 11(2):135-140.
172. Venkatachalam TK, Sudbeck EA, Mao C, Uckun FM: Piperidinylethyl, phenoxyethyl and fluoroethyl bromopyridyl thiourea compounds with potent anti-HIV activity. Antivir Chem Chemother (2000) 11(5):329- 336.
173. Venkatachalam TK, Sudbeck EA, Mao C, Uckun FM: Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. Bioorg Med Chem Lett (2001) 11(4):523-528.
174. Bell FW, Cantrell AS, Högberg M, Jaskunas SR, Johansson NG, Jordan CL, Kinnick MD, Lind P, Morin JM, Noréen R, Oberg B et al: Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs. J Med Chem (1995) 38(25):4929-4936.
175. Uckun FM, Qazi S, Venkatachalam T: N′-[2-(2-thiophene) ethyl]-N′-[2-(5-bromopyridyl)]thiourea (HI-443), a rationally designed non-nucleoside reverse transcriptase inhibitor compound with potent anti-HIV activity. Arzneimittelforschung (2007) 57(5):278-285.
176. Uckun FM, Tibbles H, Erbeck D, Venkatachalam TK, Qazi S: In vivo pharmacokinetics and toxicity of a novel hydrophilic oral formulation of the potent non-nucleoside reverse transcriptase inhibitor compound N′-[2-(2-thiophene)ethyl]-N′-[2-(5- bromopyridyl)]-thiourea (HI-443). Arzneimittelforschung (2007) 57(4):218-226.
177. D'Cruz OJ, Samuel P, Uckun FM: PHI-443: A novel noncontraceptive broad-spectrum anti-human immunodeficiency virus microbicide. Biol Reprod (2004) 71(6):2037-2047. • This paper reports the discovery of a thiophene thiourea NNRTI as a promising anti-HIV-1 microbicide.
178. D'Cruz OJ, Uckun FM: Discovery of 2,5-dimethoxy-substituted 5-bromopyridyl thiourea (PHI-236) as a potent broadspectrum anti-human immunodeficiency virus microbicide. Mol Hum Reprod (2005) 11(10):767-777. • This paper reports the discovery of a pyridyl thiourea NNRTI as a promising anti-HIV-1 microbicide.
179. Barnard J, Borkow G, Parniak MA: The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry (1997) 36(25):7786-7792.
180. Borkow G, Barnard J, Nguyen TM, Belmonte A, Wainberg MA, Parniak MA: Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: Retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J Virol (1997) 71(4):3023-3030.
181. Balzarini J, Naesens L, Verbeken E, Laga M, Van Damme L, Parniak M, Van Mellaert L, Anné J, De Clercq E: Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS (1998) 12(10):1129-1138.
182. D'Cruz OJ, Venkatachalam TK, Uckun FM: Novel thiourea compounds as dual-function microbicides. Biol Reprod (2000) 63(1):196-205. • This paper describes the unique characteristics of thiourea NNRTI inhibitors as topical anti-HIV-1 agents.
183. Pani A, Musiu C, Loi AG, Mai A, Loddo R, LaColla P, Marongiu ME: DABOs as candidates to prevent mucosal HIV transmission. Antivir Chem Chemother (2001) 12(Suppl 1):51-59.
184. Van Herrewege Y, Penne L, Vereecken C, Fransen K, van der Groen G, Kestens L, Balzarini J, Vanham G: Activity of reverse transcriptase inhibitors in monocyte-derived dendritic cells: A possible in vitro model for postexposure prophylaxis of sexual HIV transmission. AIDS Res Hum Retroviruses (2002) 18(15):1091-1102.
185. Motakis D, Parniak MA: A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother (2002) 46(6):1851-1856.
186. Van Herrewege Y, Michiels J, Van Roey J, Fransen K, Kestens L, Balzarini J, Lewi P, Vanham G, Janssen P: In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother (2004) 48(1):337-339.
187. D'Cruz OJ, Uckun FM: Stampidine: A selective oculo-genital microbicide. J Antimicrob Chemother (2005) 56(1):10-19. • This paper discusses a novel prodrug of stavudine with potent anti-HIV and anti-adenovirus activity.
188. D'Cruz OJ, Uckun FM: Mucosal safety studies PHI-443 and stampidine as combination microbicide against genital transmission of HIV-1. Fertil Steril (2007) 88(Suppl 4):1197-1206. • In vivo compatibility of a combination formulation of NRTI prodrug and thiourea NNRTI as a nontoxic broad-spectrum anti-HIV-1 microbicide.
189. D'Cruz OJ, Samuel P, Uckun FM: Conceival, a novel noncontraceptive vaginal vehicle for lipophilic microbicides. AAPS PharmSciTech (2005) 6(1):E56-E64.
190. D'Cruz OJ, Samuel P, Waurzyniak B, Uckun FM: In vivo evaluation of a gel formulation of stampidine, a novel nonspermicidal broad-spectrum anti-HIV microbicide. Am J Drug Deliv (2003) 1(4):275-285.
191. D'Cruz OJ, Samuel P, Waurzyniak B, Uckun FM: Development and evaluation of a thermoreversible ovule formulation of stampidine, a novel nonspermicidal broad-spectrum antihuman immunodeficiency virus microbicide. Biol Reprod (2003) 69(6):1843-1851.
192. D'Cruz OJ, Uckun FM: Stampidine is a nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide. Fertil Steril (2003) 81(Suppl 1):831-841. • This paper describes the unique features of a novel aryl phosphate derivative of stavudine with potent anti-HIV activity as a topical microbicide.
193. D'Cruz OJ, Erbeck D, Uckun FM: Developmental safety profile of the anti-HIV agent stampidine in rabbits. Arzneimittelforschung (2006) 56(2a):159-166.
194. D'Cruz OJ, Erbeck D, Uckun FM: A study of the potential of the pig as a model for the vaginal irritancy of benzalkonium chloride in comparison to the nonirritant microbicide PHI-443 and the spermicide vanadocene dithiocarbamate. Toxicol Pathol (2005) 33(4):465-476. • This paper reports the development of a physiologically relevant and sensitive animal model for the local tolerance of microbicide and spermicide formulations.
195. DuMez D, Venkatachalam TK, Uckun FM: Large-scale synthesis and formulation of GMP-grade stampidine, a new anti-HIV agent. Arzneimittelforschung (2006) 56(2a):136-151.
196. Dumez D, Venkatachalam TK, Uckun FM: Large-scale synthesis of GMP grade N′-[2-(2-thiophene)ethyl]-N′- [2-(5-bromopyridyl)] thiourea [PHI-443], a new anti-HIV drug candidate. Arzneimittelforschung (2007) 57(6):330-339.